Top 10 Companies in the Pharmaceutical Grade Lactic Acid Market (2026): Market Leaders Powering Global Pharmaceutical Innovation

MARKET INSIGHTS

The global pharmaceutical grade lactic acid market size was valued at USD 62 million in 2024. The market is projected to grow from USD 64.3 million in 2025 to USD 86.73 million by 2032, exhibiting a CAGR of 3.8% during the forecast period.

Pharmaceutical grade lactic acid is a high‑purity organic compound widely used in medical applications due to its biocompatibility and versatile properties. This pharmaceutical excipient plays critical roles in intravenous fluid formulations, pH regulation, and as a moisturizing agent in topical medications. The compound meets stringent pharmacopeia standards (USP/EP) for purity and is manufactured through fermentation or chemical synthesis processes.

The market growth is driven by increasing demand for biodegradable polymers in medical devices and expanding applications in drug formulations. While North America currently dominates with 27.8% market share, Asia‑Pacific shows the fastest growth potential due to pharmaceutical industry expansion. Key players like Corbion and Galactic are investing in capacity expansions to meet rising demand, particularly for high‑purity (88%) pharmaceutical grade variants used in critical care applications.

Pharmaceutical Grade Lactic Acid Market – View in Detailed Research Report

Top 10 Companies in the Pharmaceutical Grade Lactic Acid Market (2026)

---

🔟 1. Corbion N.V.

Headquarters: Amstelveen, Netherlands
Key Offering: Pharmaceutical grade lactic acid (USP & EP) for injectable solutions, pH regulation, and biodegradable polymer precursors

Corbion has established a robust fermentation platform that consistently delivers >90% purity lactic acid, meeting the most demanding compendial standards. The company’s recent expansion of a 120,000‑ton/year plant in the Netherlands is designed to support its growing portfolio of high‑purity APIs and PLA feedstock.

Sustainability & Growth Initiatives:

• Investment in renewable feedstock sourcing (corn, sugarcane) to reduce carbon footprint
• Partnership with TotalEnergies for a joint PLA facility in Thailand
• Targeting 30% increase in production capacity by 2028

---

🟨 2. Galactic S.A.

Headquarters: Brussels, Belgium
Key Offering: High‑purity lactic acid for IV solutions, active pharmaceutical ingredients, and PLA production

Galactic’s vertically integrated supply chain allows it to provide end‑to‑end solutions from raw material procurement to finished product. Its flagship 100,000‑ton/year facility in Belgium incorporates advanced membrane separation technology, boosting yield and reducing water consumption.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water recycling in all manufacturing sites
• Commitment to achieve net‑zero emissions by 2035
• Strategic acquisition of a mid‑sized Asian fermentation partner

---

🟧 3. Musashino Chemical Laboratory Ltd.

Headquarters: Tokyo, Japan
Key Offering: USP‑grade lactic acid for injectable drugs and advanced drug delivery systems

Musashino leverages its long‑standing expertise in pharmaceutical chemistry to produce lactic acid with sub‑ppm impurity levels, essential for biologics and biosimilars. The company recently launched a 50,000‑ton/year plant in Osaka, focused on high‑purity demand.

Sustainability & Growth Initiatives:

• Investment in green chemistry R&D for low‑energy fermentation
• Partnership with Japanese universities for talent development
• Expansion into the Southeast Asian market through joint ventures

---

🟪 4. Henan Jindan Lactic Acid Technology Co., Ltd.

Headquarters: Zhengzhou, China
Key Offering: API‑grade lactic acid for generic drug manufacturers and PLA feedstock

Henan Jindan has rapidly scaled its production to meet China’s growing domestic pharmaceutical demand. The company’s state‑of‑the‑art purification line achieves >95% purity, enabling it to serve both domestic and export markets.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources for plant operations
• Implementation of digital traceability for raw materials
• Expansion of regional distribution network across Asia‑Pacific

---

🟫 5. Jungbunzlauer Suisse AG

Headquarters: Zurich, Switzerland
Key Offering: Ultra‑high purity lactic acid for antibody‑drug conjugates and advanced drug delivery

Jungbunzlauer’s patented continuous chromatography system delivers >99.5% purity while reducing water usage by 30%. The company’s focus on high‑purity production supports the growing demand for complex biologics.

Sustainability & Growth Initiatives:

• Investment in membrane separation technology to lower energy consumption
• Collaboration with EU green chemistry programs
• Expansion of capacity in the European market

---

🟠 6. BBCA Group

Headquarters: Guangzhou, China
Key Offering: 80‑88% purity lactic acid for generic drug manufacturers and PLA production

BBCA has built a vertically integrated production chain, from raw material sourcing to final product. The company’s 70,000‑ton/year plant in Guangdong uses advanced fermentation and purification technologies to meet global quality standards.

Sustainability & Growth Initiatives:

• Implementation of green energy solutions across all plants
• Participation in China’s “Made in China 2025” strategic initiative
• Expansion into the European market through strategic partnerships

---

🟢 7. Luoyang Longmen Pharmaceutical Co., Ltd.

Headquarters: Luoyang, China
Key Offering: USP‑grade lactic acid for injectable solutions and drug formulations

Luoyang Longmen has focused on high‑purity production to support the domestic pharmaceutical industry’s shift toward premium APIs. The company’s 60,000‑ton/year plant incorporates advanced purification modules.

Sustainability & Growth Initiatives:

• Adoption of renewable feedstocks for fermentation
• Investment in digital supply chain management
• Expansion into the ASEAN market through joint ventures

---

🟣 8. Imperial Chemical Industries (ICI)

Headquarters: London, United Kingdom
Key Offering: Pharmaceutical grade lactic acid for injectable solutions and polymer feedstock

ICI has leveraged its extensive chemical engineering expertise to produce high‑purity lactic acid at scale. Its new 80,000‑ton/year plant in the UK focuses on sustainable production and compliance with UK GMP standards.

Sustainability & Growth Initiatives:

• Implementation of carbon capture and storage at production sites
• Partnership with UK universities for green chemistry research
• Expansion of export capacity to the EU and North America

---

🔵 9. Lallemand Inc.

Headquarters: Montreal, Canada
Key Offering: Fermentation‑based lactic acid for pharmaceutical applications and biodegradable polymer precursors

Lallemand’s bioprocessing platform utilizes yeast fermentation to produce lactic acid with high yield and purity. The company’s focus on sustainability aligns with Canadian environmental standards.

Sustainability & Growth Initiatives:

• Use of agricultural waste streams as fermentation feedstock
• Investment in energy‑efficient bioreactors
• Strategic expansion into the U.S. market through partnerships

---

🟤 10. Amgen Biologics

Headquarters: Thousand Oaks, USA
Key Offering: High‑purity lactic acid for biologics manufacturing and advanced drug delivery systems

Amgen Biologics integrates lactic acid into its biologics production pipeline, ensuring optimal buffer capacity and product stability. The company’s recent investment in a 50,000‑ton/year plant in California enhances its supply reliability.

Sustainability & Growth Initiatives:

• Commitment to net‑zero emissions by 2040
• Investment in renewable energy for plant operations
• Partnerships with academic institutions for biologics research

---

Download FREE Sample Report: Pharmaceutical Grade Lactic Acid Market – View in Detailed Research Report

Get Full Report: Pharmaceutical Grade Lactic Acid Market – View in Detailed Research Report

OUTLOOK

Global demand for pharmaceutical grade lactic acid is projected to rise steadily, driven by the expansion of biodegradable polymer manufacturing, advanced drug delivery systems, and the growing need for high‑purity excipients in IV solutions. The Asia‑Pacific region will lead growth, fueled by domestic pharmaceutical manufacturing and favorable government policies. North America and Europe will maintain stable demand, supported by stringent regulatory requirements and a focus on biologics.

FUTURE TRENDS

• Accelerated adoption of PLA‑based medical devices and packaging.
• Integration of lactic acid into nanoparticle‑based drug delivery platforms.
• Continued investment in green fermentation technologies to reduce energy consumption and CO₂ emissions.
• Expansion of supply chains to mitigate raw material concentration risks.
• Growth in emerging markets (Southeast Asia, Latin America) as local manufacturing capabilities mature.